Incyte (INCY) reported a breakout quarter on Oct. 28, beating Wall Street’s revenue and earnings estimates. Best known for its blockbuster drug Jakafi and expanding oncology pipeline, this biotech combines profitability, pipeline depth, and long-term growth potential while trading under $100. Valued at $18.2 billion, Incyte stock is up 31.9% year-to-date, outperforming the broader market gain of 17.3%. Should you grab this biotech stock now? More News from Barchart www.barchart.com About Incyte Incyte ...